Cooley advised the underwriters on Aquestive Therapeutics’ $73.9 million initial public offering of 4,925,727 shares of common stock, which includes the partial exercise of the underwriters’…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
